| Verily, Santen See Ophthalmology Opportunity Via New Joint Venture | Sarah de Crescenzo | 02/04/20 | San Francisco |
| $750M Fund Looks to Software Sector to Drive Future of Biotech | Sarah de Crescenzo | 02/04/20 | National |
| Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup | Frank Vinluan | 02/04/20 | New York |
| Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic | Sarah de Crescenzo | 02/03/20 | New York |
| Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals | Sarah de Crescenzo | 02/03/20 | New York |
| United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial | Frank Vinluan | 02/03/20 | National |
| Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony” | Dan Stanton | 02/03/20 | New York |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs | Sarah de Crescenzo | 01/31/20 | San Diego |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14 | Frank Vinluan | 01/30/20 | San Francisco |
| Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D | Frank Vinluan | 01/30/20 | Boston |
| Vizgen Launches With $14M to Market New Subcellular Imaging Technique | Sarah de Crescenzo | 01/30/20 | Boston |
| Annovis Bio Gets $12M in IPO to Target Trio of Neurotoxic Proteins | Sarah de Crescenzo | 01/29/20 | New York |
| Spring Bank Pharma Ends Hepatitis B Work After Death in Clinical Trial | Frank Vinluan | 01/29/20 | Boston |
| Agenda and Speakers Announced for Xcelerating Life Sciences San Diego | Editors | 01/29/20 | National |
| Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus | Frank Vinluan | 01/29/20 | Boston |
| Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets | Sarah de Crescenzo | 01/28/20 | San Diego |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Flagship Adds Fertility-Focused Ohana Biosciences to Biotech Family | Sarah de Crescenzo | 01/27/20 | Boston |
| Quench Bio Springs From Atlas With $50M for a New Take on Inflammation | Frank Vinluan | 01/27/20 | Boston |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie | Frank Vinluan | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| Epizyme’s Soft Tissue Cancer Drug Granted Speedy FDA Approval | Frank Vinluan | 01/23/20 | Boston |
| After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune | Mike Ward | 01/23/20 | National |
| FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs | Frank Vinluan | 01/22/20 | Boston |
